{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-104993","form_type":"8-K","ticker":"SONM","cik":"0001178697","company_name":"DNA X, Inc.","filed_at":"2022-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.952209+00:00","generated_at":"2026-06-26T07:17:24.985282+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sonim enters $17.5M subscription agreement with AJP; Peter Liu appointed CEO","bullets":["AJP to buy 20.8M shares at $0.84/share for $17.5M; post-transaction AJP owns ~52%.","Peter Liu appointed CEO effective April 14, 2022; he is part of AJP investment group.","First closing of $12.5M for 14.9M shares requires stockholder approval; second closing of $5M later.","Board reconstituted with AJP designees; Robert Tirva to resign at first closing with $1M severance.","Strategy shift: expand into semi-rugged and industrial 5G markets using ODM relationships."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-104993","json":"https://secwatch.observer/filing/0001193125-22-104993.json","markdown":"https://secwatch.observer/filing/0001193125-22-104993.md","text":"https://secwatch.observer/filing/0001193125-22-104993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178697/000119312522104993/0001193125-22-104993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178697/000119312522104993/d325458d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:17:24.985282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1395fefdfe","claim":"Robert Tirva was terminated as President, Chief Financial Officer and Chief Operating Officer at DNA X, Inc..","evidence_excerpt":"On April 13, 2022, the Compensation Committee of the Board of Directors of the Company approved a letter agreement with Robert Tirva, the Company’s President, Chief Financial Officer and Chief Operating Officer. The agreement provides that Mr. Tirva’s employment with the Company will terminate on, and subject to, the First Closing and that upon such termination, Mr. Tirva would be entitled to receive","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000119312522104993/0001193125-22-104993-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President, Chief Financial Officer and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"863b496ea4","claim":"Peter Liu was appointed as Chief Executive Officer at DNA X, Inc..","evidence_excerpt":"on April 13, 2022, the board of directors of Sonim appointed Peter Liu as Chief Executive Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000119312522104993/0001193125-22-104993-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}